7*24 Hotline：
Shenzhen Yitong Pharmaceutical Co., Ltd. (000028)
Congyi Pharmaceutical Co., Ltd (hereinafter referred to as Sinopharm Congyi) is a comprehensive pharmaceutical listed company (A-share 000028, B-share 200028) under China Pharmaceutical Group Co., Ltd. and Sinopharm Holding Co., Ltd. It is the only pharmaceutical retail integration platform of Sinopharm group in China. Its business covers the whole industry chain of "pharmaceutical distribution + pharmaceutical logistics + pharmaceutical retail + industrial investment", with 110 subsidiaries and more than 30000 employees. The operating revenue in 2019 is expected to exceed 50 billion yuan, ranking 51st among the top 500 enterprises in Guangdong Province and 24th among the top 100 enterprises in Shenzhen city. Responsible for the central, provincial (Guangdong, Guangxi) and municipal (Guangzhou, Shenzhen, Nanning, etc.) special drug and equipment commodity reserve and the allocation and supply of drugs for emergency and disaster relief all over the country.
In the field of drug distribution, Sinopharm has established itself as an "excellent medical supply chain solution and service provider" and formed a strong business network in southern China with its integrated and large-scale industrial advantages. Up to now, the company has 47 subsidiaries in Guangzhou, Shenzhen, Foshan, Dongguan and other important regions of Guangdong and Guangxi, including Zhanjiang, Meizhou, Huizhou, Zhaoqing, Jiangmen, Shaoguan, Zhongshan, Nanning and Liuzhou. Among them, the company ranks the top three in the direct sales market competition of hospitals in 31 prefecture level cities, realizing the deep penetration in southern China. The company has built a "four in one" ladder logistics distribution network composed of regional logistics center, provincial logistics center, urban distribution center and distribution station, expanded the new mode of modern logistics operation such as multi warehouse operation, third-party logistics and cold chain management, and provided professional, efficient and fast drug distribution and logistics value-added services for customers and suppliers. In addition, the company also actively promotes business transformation and upgrading, focuses on promoting the national retail terminal business, and creates a national retail direct sales business platform. By adopting advanced supply chain management methods and modern technology, we can comprehensively carry out equipment business, expand 4D business, build the core competitiveness of SPD, and join hands with medical institutions to carry out supply chain management extension, so as to achieve cost reduction and efficiency. By the end of 2019, the distribution sales revenue will exceed 40 billion yuan.
In the field of drug retail, Sinopharm has joined hands with wobolian, the first world-class pharmaceutical and health care enterprise in the world, to build a Chinese pharmaceutical and health retail brand "Guoda pharmacy" that consumers can rest assured of. At present, 27 regional chain companies have been established in 21 provinces, autonomous regions and municipalities directly under the central government, covering 75 prefecture level cities in China, with more than 5000 retail pharmacies. In the past six years, it has been ranked first in China's pharmaceutical retail industry. Relying on advanced management capabilities, efficient and efficient procurement system, strict quality control, fine shop management, intimate chronic disease professional services, efficient logistics system, and the ERP platform, a series of professional advantages, the Bureau covers retail outlets of Chinese medicine, western medicine, Chinese medicine, western medicine, rehabilitation therapy and various medical related resources, and innovating the application of Internet plus technology. Join hands with local governments to carry out online community health construction to ensure people's health needs. In 2019, the sales revenue of Guoda pharmacy will exceed 12 billion yuan.
Sinopharm's consistent industrial investment strategy mainly participates in the R & D, production and sales of industrial enterprises, including Sinopharm Zhijun Shenzhen Pharmaceutical Co., Ltd., Sinopharm Zhijun Shenzhen Pingshan Pharmaceutical Co., Ltd., Shenzhen Zhijun Pharmaceutical Trade Co., Ltd. and Shenzhen Wanle Pharmaceutical Co., Ltd., covering anti infection, respiratory medicine, health care products, Chinese patent medicine and anti-tumor drugs. In 2019, the sales volume of the industrial investment sector will exceed 4 billion yuan.
In the future, Sinopharm will continue to uphold the principle of "caring for life" Based on the development opportunity of China's medical and health industry, we should transform, innovate and develop professionally, give full play to the collaborative effect of distribution and retail resources, promote the wholesale and retail integration strategy and international strategy, promote the company's digital transformation with scientific and technological innovation, and move towards the leading international medical and health service platform and higher scale goal!
oil wellhead